Efficacy and safety of quetiapine fumarate in the treatment of schizophrenic patients - ESPRIT

Study identifier:D1444C00008

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 6-Week, Multi-centre, Double-blind, Double-dummy, Chlorpromazine-Controlled Randomised Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Extended-Release in the Treatment of Schizophrenic Patients with Acute Episode

Medical condition

schizophrenia

Phase

Phase 3

Healthy volunteers

No

Study drug

Quetiapine Fumarate (SEROQUEL) Extended-Release (XR), Chlorpromazine

Sex

All

Actual Enrollment

388

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Apr 2009
Primary Completion Date: 01 Jul 2010
Study Completion Date: 01 Jul 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2012 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria